What's better than momentum? Mo' momentum.
Let's take a closer look at five of this past week's biggest scorchers.
|July 13||Weekly Gain||My Watchlist|
|Amerigroup (NYS: AGP)||$89.95||40%||Add|
|Affymax (NAS: AFFY)||$16.49||30%||Add|
|Orexigen Therapeutics (NAS: OREX)||$7.06||22%||Add|
|Complete Genomics (NAS: GNOM)||$2.44||18%||Add|
|SkyWest (NAS: SKYW)||$7.96||14%||Add|
Amerigroup was the picture of health, soaring nearly 40% after WellPoint struck a deal to acquire the Medicaid coverage specialist. The all-cash deal will take Amerigroup shareholders out at $92, a healthy premium to where the stock was just before the deal was announced.
Affymax was one of the market's biggest winners after a company announced that it would be rolling out Affymax's anemia drug Omontys -- a drug that boosts red blood cell production for dialysis patients -- in at least 100 dialysis centers.
Orexigen shares fattened up after the company reported strong enrollment for its diet-drug study. The heavy demand now finds Orexigen targeting interim analysis of the study concluding by early next year, a lot earlier than original expectations.
Complete Genomics was DNA -- as in Deserving Notable Appreciation -- after introducing a new technology that can potentially set the new standard for clinical-grade genomes.
Regional air carrier SkyWest took off after placing an order with Mitsubishi for 100 jets.
More winners for you
It was a great week for these five stocks. If you want to get an early read on some of tomorrow's major gainers, there's a special report on three hidden winners in a booming industry. The report is free -- like this article -- but it won't be around forever, so check it out now.
At the time this article was published The Motley Fool owns shares of WellPoint. Motley Fool newsletter services have recommended buying shares of WellPoint and Amerigroup. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.Longtime Fool contributor Rick Munarriz calls them as he sees them. He does not own shares in any of the stocks in this story. Rick is also part of the Rule Breakers newsletter research team, seeking out tomorrow's ultimate growth stocks a day early.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.